Schwabe Stefan K.F. 4
4 · SUPERNUS PHARMACEUTICALS INC · Filed Sep 11, 2017
Insider Transaction Report
Form 4
Schwabe Stefan K.F.
Executive Vice President R&D
Transactions
- Exercise/Conversion
Common Stock
2017-09-07$12.92/sh+95,000$1,227,400→ 96,855 total - Sale
Common Stock
2017-09-07$46.59/sh−95,000$4,425,575→ 1,855 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2017-09-07−95,000→ 0 totalExercise: $12.92Exp: 2022-08-09→ Common Stock (95,000 underlying)
Footnotes (4)
- [F1]Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017.
- [F2]Includes an aggregate of 324 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.000 to $47.800, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- [F4]The option became exercisable in four equal installments beginning on August 9, 2013, which was the first anniversary of the date on which the option was granted.